WallStreetZenWallStreetZen

NASDAQ: TSHA
Taysha Gene Therapies Inc Stock Ownership - Who owns Taysha Gene Therapies?

Insider buying vs selling

Have Taysha Gene Therapies Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Kamran AlamCHIEF FINANCIAL OFFICER2024-02-021,288$1.51
$1.94kSell
Paul B. Manning10% Owner2023-11-17100,000$1.63
$163.00kBuy
Kamran AlamChief Financial Officer2023-08-2433,000$2.33
$76.89kSell
Sean P. NolanChief Executive Officer2023-08-16444,444$0.90
$400.00kBuy
John A. Stalfort IiiDirector2023-08-16388,889$0.90
$350.00kBuy
Phillip B. DonenbergDirector2023-08-16111,111$0.90
$100.00kBuy
Paul B. Manning10% Owner2023-08-1616,466,667$0.90
$14.82MBuy
John A. Stalfort IiiDirector2023-08-16388,889$0.90
$350.00kBuy
Ra Session Ii10% Owner2023-07-135,344$0.70
$3.74kSell
Ra Session Ii10% Owner2023-07-1280,528$0.71
$57.01kSell

1 of 2

TSHA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TSHA insiders and whales buy or sell their stock.

TSHA Shareholders

What type of owners hold Taysha Gene Therapies Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Fmr LLC10.75%20,110,717$59.53MInstitution
Avoro Capital Advisors LLC9.97%18,650,000$55.20MInstitution
Rtw Investments LP9.94%18,593,185$55.04MInstitution
Ra Capital Management LP5.81%10,872,503$32.18MInstitution
Ra Session Ii4.82%9,012,837$26.68MInsider
Vr Adviser LLC4.81%9,000,000$26.64MInstitution
Audentes Therapeutics Inc3.89%7,266,342$21.51MInsider
Paul B. Manning3.46%6,479,609$19.18MInsider
Vanguard Group Inc3.16%5,917,414$17.52MInstitution
Morgan Stanley2.76%5,168,890$15.30MInstitution

1 of 3

TSHA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TSHA74.94%15.93%Net Buying
MLYS60.60%39.40%Net BuyingNet Buying
PHAT61.86%38.14%Net SellingNet Selling
ZYME62.27%37.73%Net Buying
EXAI25.00%0.00%

Taysha Gene Therapies Stock Ownership FAQ

Who owns Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ: TSHA) is owned by 74.94% institutional shareholders, 15.93% Taysha Gene Therapies insiders, and 9.13% retail investors. Ra Session Ii is the largest individual Taysha Gene Therapies shareholder, owning 9.01M shares representing 4.82% of the company. Ra Session Ii's Taysha Gene Therapies shares are currently valued at $29.20M.

If you're new to stock investing, here's how to buy Taysha Gene Therapies stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.